Publications2023-08-23T10:08:45-04:00

Molecular-Guided Therapy for the Treatment of Relapsed/Refractory Neuroblastoma: Results from Beat Childhood Cancer Research Consortium Trial MGT009

Molecular-Guided Therapy for the Treatment of Relapsed/Refractory Neuroblastoma: Results from Beat Childhood Cancer Research Consortium Trial MGT009 Jaqueline Kraveka, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier[...]

Abstract|

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma

Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A,[...]

Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy

Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy Jaqueline Kraveka, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Donald A. Berry, Javier Oesterheld,[...]

Abstract|

Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls

Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving Eflornithine (DFMO) Maintenance Treatment with Matched External Controls, Giselle Saulner Sholler, William Ferguson, Genevieve Bergendahl, Thomas Clinch, Elizabeth[...]

Abstract|

Molecular-guided therapy for the treatment of relapsed neuroblastoma: A Beat Childhood Cancer Research Consortium Trial

Giselle L. Saulnier Sholler, MD, MS1, Elizabeth C. Lewis1, Jacqueline Kraveka, DO2, William Ferguson, MD3, Abhinav B. Nagulapally, MS1, Karl Dykema1, Genevieve Bergendahl, MSN1,  Valerie I. Brown, MD, PhD4, Michael[...]

Abstract|

Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database

Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database,  Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry,[...]

Abstract|

Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance

Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance. Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry, Elizabeth Lorenzi, Thomas Clinch, Jacqueline[...]

Abstract|

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma

Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter[...]

Go to Top